Gemcitabine trials for Metastatic Pancreatic Adenocarcinoma

All Gemcitabine trials · All Metastatic Pancreatic Adenocarcinoma trials

Phase breakdown

Recruiting trials studying Gemcitabine for Metastatic Pancreatic Adenocarcinoma

• AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
  NCT07619313 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
  NCT07226856 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
  NCT06576115 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
  NCT06998940 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 274 locations

Common questions

How many trials study Gemcitabine for Metastatic Pancreatic Adenocarcinoma?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.